Polymer coatings containing drug powder of controlled morphology
First Claim
1. A method for coating a substrate, said coating comprising at least one polymer;
- and at least one pharmaceutical agent in a therapeutically desirable morphology;
said method comprising the following steps;
a) discharging the at least one pharmaceutical agent in dry powder form through a first orifice;
discharging the at least one polymer in dry powder form through a second orifice;
depositing polymer and pharmaceutical agent particles onto said substrate, wherein an electrical potential is maintained between the substrate and the polymer and pharmaceutical agent particles, thereby forming said coating; and
thenb) sintering said coating under conditions that do not substantially modify the morphology of said pharmaceutical agent, wherein said sintering comprises treating said coated substrate with a compressed gas, compressed liquid or supercritical fluid that is a non-solvent for both the polymer and the pharmaceutical agent, wherein the therapeutically desirable morphology of said pharmaceutical agent is crystalline or semi-crystalline.
7 Assignments
0 Petitions
Accused Products
Abstract
A method for depositing a coating comprising a polymer and pharmaceutical agent on a substrate, comprising the following steps: discharging at least one pharmaceutical agent in a therapeutically desirable morphology in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second orifice; depositing the polymer and/or pharmaceutical particles onto the substrate, wherein an electrical potential is maintained between the substrate and the pharmaceutical and/or polymer particles, thereby forming the coating; and sintering the coating under conditions that do not substantially modify the morphology of the pharmaceutical agent.
-
Citations
18 Claims
-
1. A method for coating a substrate, said coating comprising at least one polymer;
- and at least one pharmaceutical agent in a therapeutically desirable morphology;
said method comprising the following steps;a) discharging the at least one pharmaceutical agent in dry powder form through a first orifice;
discharging the at least one polymer in dry powder form through a second orifice;
depositing polymer and pharmaceutical agent particles onto said substrate, wherein an electrical potential is maintained between the substrate and the polymer and pharmaceutical agent particles, thereby forming said coating; and
thenb) sintering said coating under conditions that do not substantially modify the morphology of said pharmaceutical agent, wherein said sintering comprises treating said coated substrate with a compressed gas, compressed liquid or supercritical fluid that is a non-solvent for both the polymer and the pharmaceutical agent, wherein the therapeutically desirable morphology of said pharmaceutical agent is crystalline or semi-crystalline. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
- and at least one pharmaceutical agent in a therapeutically desirable morphology;
Specification